SCHEMBL7011064

SCHEMBL7011064

COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3n2S(=O)(=O)c2cccnc2)c1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 7/20 0.41
ATP4B P51164 7/20 0.41
CYP2C9 P11712 1/20 0.41
KDM4E B2RXH2 1/20 0.41
SLC22A2 O15244 1/20 0.41
DDAH1 O94760 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
ABCB1 P08183 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
ADRA1A P35348 1/20 0.41
FASN P49327 1/20 0.41
SLC47A2 Q86VL8 1/20 0.41
SLC47A1 Q96FL8 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
ATP1A1 P05023 3/20 0.34
ATP1B1 P05026 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7014451 0.94 ATP4A (0.42) ATP4AATP4BCYP2C9KDM4ESLC22A2
SCHEMBL7007925 0.93 ATP4A (0.43) ATP4AATP4BCYP2C9KDM4ESLC22A2
SCHEMBL7008228 0.91 ATP4A (0.44) ATP4AATP4BCYP2C9KDM4ESLC22A2
SCHEMBL7009441 0.89 ATP4A (0.43) ATP4AATP4BCYP2C9KDM4ESLC22A2
SCHEMBL7006711 0.89 ATP4A (0.43) ATP4AATP4BCYP2C9KDM4ESLC22A2
SCHEMBL7007909 0.89 ATP4A (0.42) ATP4AATP4BCYP2C9KDM4ESLC22A2
SCHEMBL12353527 0.89 ATP4A (0.42) ATP4AATP4BCYP2C9KDM4ESLC22A2
SCHEMBL7012531 0.89 ATP4A (0.42) ATP4AATP4BCYP2C9KDM4ESLC22A2
SCHEMBL14465232 0.89 ATP4A (0.42) ATP4AATP4BCYP2C9KDM4ESLC22A2
SCHEMBL5764473 0.88 ATP4A (0.39) ATP4AATP4BCYP2C9KDM4ESLC22A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US claimed
EP-1105387-B1 PRODRUGS OF PROTON PUMP INHIBITORS WINSTON PHARMATEUTICALS LLC (US) 2003-01-29 EP claimed
EP-1105387-A1 PRODRUGS OF PROTON PUMP INHIBITORS Partnership of Michael E. Garst, George Sachs and Jai Moo Shin (US) 2001-06-13 EP claimed
WO-2000009498-A1 PRODRUGS OF PROTON PUMP INHIBITORS PARTNERSHIP OF MICHAEL E. GARST, GEORGE SACHS AND JAI MOO SHIN (US) 2000-02-24 WO claimed
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US disclosed
EP-1105387-B1 PRODRUGS OF PROTON PUMP INHIBITORS WINSTON PHARMATEUTICALS LLC (US) 2003-01-29 EP disclosed
EP-1105387-A1 PRODRUGS OF PROTON PUMP INHIBITORS Partnership of Michael E. Garst, George Sachs and Jai Moo Shin (US) 2001-06-13 EP disclosed
WO-2000009498-A1 PRODRUGS OF PROTON PUMP INHIBITORS PARTNERSHIP OF MICHAEL E. GARST, GEORGE SACHS AND JAI MOO SHIN (US) 2000-02-24 WO disclosed